| Literature DB >> 30845176 |
Michelle L Meyer1, Feng-Chang Lin2, Andrea Jaensch3, Ute Mons4, Harry Hahmann5, Wolfgang Koenig6,7,8, Hermann Brenner4,9, Dietrich Rothenbacher3,4.
Abstract
OBJECTIVE: Patients with coronary heart disease (CHD) commonly suffer from depression and anxiety, yet transitions of symptom severity and cardiovascular events (CVE) over time are not well characterized.Entities:
Mesh:
Year: 2019 PMID: 30845176 PMCID: PMC6405099 DOI: 10.1371/journal.pone.0213334
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Multistate model of transitions in depression or anxiety symptom severity and a cardiovascular event (CVE).
Demographic and clinical characteristics in patients with coronary heart disease (n = 997).
| Characteristics at baseline | Mean (SD) or N (%) |
|---|---|
| Age, years, mean (SD) | 58.9 (8.0) |
| Female, n (%) | 150 (15.1) |
| Body mass index, Kg/m2, mean (SD) | 26.9 (3.2) |
| School education <10 years | 597 (59.9) |
| Married, n (%) | 842 (84.5) |
| Former/current smoker, n (%) | 667 (66.9) |
| Physical activity at year one, n (%) | |
| PA level 1, daily or 5-6x/week | 310 (31.2) |
| PA level 2, 2-4x/week | 417 (42.0) |
| PA level 3, 1x/week or 1-3x/month | 180 (18.1) |
| PA level 4, seldom or never | 87 (8.8) |
| History of myocardial infarction, n (%) | 570 (57.2) |
| History of type 2 diabetes, n (%) | 161 (16.2) |
| Clinical score (angiographic evaluation) | |
| 0 or 1 vessel disease | 259 (27.2) |
| 2 vessel disease | 269 (28.3) |
| 3 vessel disease | 423 (44.5) |
| Medication use, n (%) | |
| Anti-depression | 20 (2.0) |
| Anti-anxiety | 18 (1.8) |
| Beta‐blocker | 873 (87.7) |
| ACE‐inhibitor | 519 (52.2) |
| Lipid-lowering | 761 (76.5) |
| HADS-depression score, n (%) | |
| <8, no symptoms | 827 (82.9) |
| 8‐10, mild symptoms | 114 (11.4) |
| ≥11, moderate/severe symptoms | 56 (5.6) |
| HADS-anxiety score, n (%) | |
| <8, no symptoms | 765 (76.7) |
| 8‐10, mild symptoms | 157 (15.7) |
| ≥11, moderate/severe symptoms | 75 (7.5) |
SD, standard deviation; PA, physical activity; HADS, Hospital Anxiety and Depression Scale.
a3 missing
b46 missing
c2 missing.
Fig 2Transitions in (A) depression and (B) anxiety symptom severity and a cardiovascular event (CVE) at 5 years by age group with adjustments for sex, body mass index, smoking, education, diabetes, myocardial infarction, physical activity and anti-depression/anxiety medication; transition probabilites are shown at the reference level, N = 997.
Fig 3Transitions in (A) depression and (B) anxiety symptom severity and a cardiovascular event (CVE) at 5 years by physical activity (PA) group with adjustments for sex, body mass index, smoking, education, diabetes, myocardial infarction, physical activity and anti-depression/anxiety medication; transition probabilites are shown at the reference level, N = 997.
Association of explanatory variables with depression symptom severity progression, regression, and cardiovascular event.
Depression Level 1 = No Symptoms (<8), 2 = Mild (8–10), 3 = Moderate/Severe (≥11).
| Progression | Regression | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1→2 | 1→3 | 2→3 | 2→1 | 3→1 | 3→2 | ||||
| Variables | TIR | TIR | TIR | TIR | TIR | TIR | |||
| Age | 1.0 | 1.1 (0.8,1.6) | 1.1 | 0.9 | 0.7 | ||||
| Female Sex | 1.0 | 0.8 | 0.8 | 1.2 | 1.4 | 0.9 | |||
| BMI | 0.8 | 1.1 | 0.7 | 1.2 | |||||
| Current/former smoker | 0.9 | 1.4 | 1.1 | 0.9 | 0.7 | 1.3 | |||
| Education <10 years | 1.1 | 1.1 | 1.8 | 0.9 | |||||
| History of diabetes | 1.1 | 1.5 | 1.3 | 1.2 | 1.1 | 1.0 | |||
| History of myocardial infarction | 1.0 | 1.4 | 0.9 | 1.2 | 0.9 | ||||
| Lower physical activity level | 1.2 | 0.8 | |||||||
| Anti-depression meds | 0.9 | 1.6 | 0.9 | 0.6 | 0.3 | ||||
| Anti-anxiety meds | 0.8 | 1.6 | 1.4 | 1.2 | 1.9 | 3.5 | |||
Depression level 1 = no symptoms (<8), 2 = mild (8–10), 3 = moderate/severe (≥11); TIR, Transition Intensities Ratio; 95% CI, 95% Confidence Interval; CVE, cardiovascular event; BMI, body mass index.
aTIR estimates are adjusted for age (< 55 yr, 55–64 yr, and > 64 yr), female sex, body mass index (BMI; <25 kg/m2 normal, 25–29.9 kg/m2 overweight, and ≥30 kg/m2 obese), current/former smoker, education <10 years, history of diabetes, history of myocardial infarction, lower physical activity (PA) at year one (PA level 1: daily or 5-6x/week, PA level 2: 2-4x/week, PA level 3: 1x/week or 1-3x/month, and PA level 4: seldom or never), and anti-depression/anxiety medication use. TIR is the ratio of transition intensities between the exposed group to the unexposed group and can be interpreted as relative risk (RR).
Association of explanatory variables with anxiety symptom severity progression, regression, and cardiovascular event anxiety level 1 = no symptoms (<8), 2 = mild (8–10), 3 = moderate/severe (≥11).
| Progression | Regression | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1→2 | 1→3 | 2→3 | 2→1 | 3→1 | 3→2 | ||||
| Variables | TIR | TIR | TIR | TIR | TIR | TIR (95% CI) | |||
| Age | 0.8 | 1.2 | 0.9 | 1.0 | 1.2 | ||||
| Female Sex | 1.6 | 0.8 | 1.1 | 1.6 | 1.0 | ||||
| BMI | 1.1 | 1.1 | 0.9 | 0.9 | 0.9 | 1.0 | |||
| Current/ | 0.9 | 1.4 | 1.1 | 0.9 | 1.1 | 1.6 | |||
| Education <10 years | 1.1 | 1.4 | 1.0 | 1.0 | 0.8 | 0.7 | |||
| History of diabetes | 0.7 | 1.4 | 0.6 | 1.1 | 0.9 | 1.2 | |||
| History of myocardial infarction | 1.0 | 0.9 | 1.2 | 1.1 | 0.9 | ||||
| Lower physical activity level | 1.1 | 1.1 | 1.0 | 0.8 | 0.9 | ||||
| Anti-depression meds | 1.2 | 1.2 | 0.8 | 0.6 | 0.4 | ||||
| Anti-anxiety meds | 1.8 | 1.0 | 2.0 | 0.8 | 0.8 | 2.3 | |||
Anxiety level 1 = no symptoms (<8), 2 = mild (8–10), 3 = moderate/severe (≥11); TIR, Transition Intensities Ratio; 95% CI, 95% Confidence Interval; CVE, cardiovascular event; BMI, body mass index.
aTIR estimates are adjusted for age (< 55 yr, 55–64 yr, and > 64 yr), female sex, body mass index (BMI; <25 kg/m2 normal, 25–29.9kg/m2 overweight, and ≥30 kg/m2 obese), current/former smoker, education <10 years, history of diabetes, history of myocardial infarc tion, lower physical activity (PA) at year one (PA level 1: daily or 5-6x/week, PA level 2: 2-4x/week, PA level 3: 1x/week or 1-3x/month, and PA level 4: seldom or never), and anti-depression/anxiety medication use. TIR is the ratio of transition intensities between the exposed group to the unexposed group and can be interpreted as relative risk (RR).